(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[3-[2-[2-[2-[2-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoyl]amino]-3-phenyl-propanoyl]amino]-5-guanidino-pentanoyl]amino]-5-guanidino-pentanoyl]amino]-5-oxo-pentanoyl]amino]-5-guanidino-pentanoyl]pyrrolidine-2-carbonyl]amino]-5-guanidino-pentanoyl]-methyl-amino]-4-methyl-pentanoyl]amino]-3-hydroxy-propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-2-methyl-propanoyl]amino]-3-(4-bromophenyl)propanoic acid

ID: ALA4472749

Chembl Id: CHEMBL4472749

PubChem CID: 155536031

Max Phase: Preclinical

Molecular Formula: C127H198BrN35O29

Molecular Weight: 2759.10

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)CCOCCOCCOCCOCCOCCOCCNC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)NC(C)(C)C(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)O

Standard InChI:  InChI=1S/C127H198BrN35O29/c1-7-8-32-92(114(176)160-127(4,5)121(184)159-98(120(182)183)71-80-41-43-81(128)44-42-80)153-115(177)100-39-24-55-162(100)105(167)74-146-106(168)88(33-16-18-48-129)149-112(174)97(72-82-73-140-77-147-82)157-113(175)99(75-164)158-117(179)102(69-78(2)3)161(6)118(180)94(37-22-52-143-124(136)137)155-116(178)101-40-25-56-163(101)119(181)95(38-23-53-144-125(138)139)154-110(172)93(45-46-103(131)165)152-109(171)90(35-20-50-141-122(132)133)150-108(170)91(36-21-51-142-123(134)135)151-111(173)96(70-79-26-10-9-11-27-79)156-107(169)89(34-17-19-49-130)148-104(166)47-57-186-59-61-188-63-65-190-67-68-191-66-64-189-62-60-187-58-54-145-126(185)192-76-87-85-30-14-12-28-83(85)84-29-13-15-31-86(84)87/h9-15,26-31,41-44,73,77-78,87-102,164H,7-8,16-25,32-40,45-72,74-76,129-130H2,1-6H3,(H2,131,165)(H,140,147)(H,145,185)(H,146,168)(H,148,166)(H,149,174)(H,150,170)(H,151,173)(H,152,171)(H,153,177)(H,154,172)(H,155,178)(H,156,169)(H,157,175)(H,158,179)(H,159,184)(H,160,176)(H,182,183)(H4,132,133,141)(H4,134,135,142)(H4,136,137,143)(H4,138,139,144)/t88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-/m0/s1

Standard InChI Key:  MANYOOSEQMUKFO-NHWMPMGMSA-N

Alternative Forms

  1. Parent:

    ALA4472749

    ---

Associated Targets(Human)

KLKB1 Tclin Plasma kallikrein (2047 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MME Tclin Neprilysin (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
APLNR Tchem Apelin receptor (3301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Aplnr Apelin receptor (201 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 2759.10Molecular Weight (Monoisotopic): 2756.4278AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Fischer C, Lamer T, Wang W, McKinnie SMK, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC..  (2019)  Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents.,  166  [PMID:30690406] [10.1016/j.ejmech.2019.01.040]

Source